市场调查报告书
商品编码
1426122
全球正子断层扫描(PET)市场评估:按产品、侦测器、应用、最终用户、地区、机会和预测(2017-2031年)Positron Emission Tomography Market Assessment, By Product, By Detector, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球正子断层扫描 (PET) 市场规模将从 2023 年的 17 亿美元增至 2031 年的 25.8 亿美元,预计在 2024-2031 年预测期内复合年增长率为 5.1%。 市场受到心臟病、中风和癌症等慢性疾病增加的影响。 慢性病的快速增加增加了对 PET 扫描等先进诊断工具的需求,PET 扫描以其准确性和早期检测能力而闻名。 另一个重要的驱动因素包括技术进步,例如解析度的提高和扫描速度的加快,这使得即使是复杂的手术也能进行精确成像,并最终提高诊断准确性和患者治疗效果。 此外,混合 PET/CT 和 PET/MRI 系统的引入正在使 PET 扫描在临床实践中多样化并提高其有效性,从而推动市场成长。
政府措施和资金也透过广泛的研发 (R&D)、基础设施扩张和报销政策推动全球正子断层扫描 (PET) 市场。 这些努力,加上业界不断增加的投资和合作伙伴关係,正在推动创新并推动 PET 技术的发展。 此外,由于人口老化迅速增加,与年龄相关的疾病日益流行,增加了PET检查的需求。 人们对 PET 影像的认识和接受度不断提高,及其向神经病学和心臟病学等领域的扩展,进一步巩固了其作为诊断工具的重要作用。
扩展PET扫描的应用
正子断层扫描 (PET) 影像的应用范围不断扩大是市场扩张的主要驱动力。 最初,PET 影像因其在肿瘤诊断方面的优越性而被认可,但现在它已被应用于神经病学和心臟病学等多个医学领域。 PET 技术的进步和新型放射性追踪剂的开发不断扩大 PET 的用途,使医疗保健专业人员能够更深入地研究疾病机制、治疗反应和个人化医疗方法。 应用的增加不仅提高了患者护理标准,而且增加了对 PET 成像系统的需求,为全球 PET 市场的渗透和持续增长做出了重大贡献。 此外,最大限度地提高设备的灵敏度可以减少剂量并提供更快的诊断,从而扩展 PET 扫描在整个医学领域的应用。
建立研究机构
新研究设施的建立是全球正子断层扫描 (PET) 市场的主要驱动因素。 这些中心作为创新中心,促进尖端 PET 影像技术、放射性追踪剂和方法的进步。 这些中心促进合作研究,支持各种医学应用的研究,并帮助提高 PET 在诊断和追踪各种疾病状况方面的有效性。 除了吸引投资和研究合作外,这些努力还将加速 PET 技术的发展并增加其对医疗保健的影响。 这个过程刺激了市场扩张并确保诊断能力的持续进步。
例如,澳洲国家全身 PET 设施于 2023 年 12 月 12 日成立。 该设施将推动癌症研究、神经系统疾病、心血管疾病研究、药物开发等方面的进展。 该设施的推出旨在透过最大限度地减少扫描时间和辐射暴露来彻底改变患者护理标准。
政府措施
世界各国政府正积极实施策略,以加速全球正子断层扫描 (PET) 市场的发展。 这些策略包括资助研究、促进技术进步以及提高 PET 技术的可用性。 透过支持研究和开发,政府正在推动 PET 成像的发展,并促进先进成像系统和创新放射性示踪剂的开发。 此外,改善报销政策和医疗基础设施的努力在促进 PET 扫描的采用方面发挥着重要作用。 这些广泛的政府措施旨在加强 PET 市场,促进其扩张并加强其在现代诊断医学中的重要作用。
本报告研究并分析了全球正子断层扫描 (PET) 市场,提供市场规模和预测、市场动态、主要参与者现状和前景等。
Global positron emission tomography market is projected to witness a CAGR of 5.1% during the forecast period 2024-2031, growing from USD 1.7 billion in 2023 to USD 2.58 billion in 2031. The global positron emission tomography market is being influenced by the increasing prevalence of chronic diseases such as heart diseases, stroke, and cancer. This surge in chronic diseases is increasing the demand for advanced diagnostic tools like PET scans, known for their precision and early detection capabilities. Another important driver include technological advancements, such as increased resolution and fast scanning abilities, which enable precise imaging for complicated procedures, ultimately enhancing diagnostic precision and patient outcomes. Moreover, the introduction of hybrid PET/CT and PET/MRI systems have diversified and enhanced the effectiveness of PET scans in clinical settings, thereby propelling the growth of global positron emission tomography market.
Government initiatives and funding are also driving the global positron emission tomography market through extensive research and development (R&D), expansion in infrastructure, and reimbursement policies. Combined with increased investments and partnerships within the industry, these efforts encourage innovation and propel PET technology's evolution. Additionally, a burgeoning elderly population is increasing the demand for PET scans as age-related ailments become more prevalent. Growing recognition and acceptance of PET imaging, along with its expansion into fields like neurology and cardiology, is further solidifying its pivotal role as a diagnostic tool.
Growing Application of PET Scans
The growing scope of positron emission tomography (PET) imaging applications significantly drives the market expansion. Initially recognized for its dominance in oncology diagnostics, PET imaging now spans diverse medical domains like neurology and cardiology. With the evolution of PET technology and the development of novel radiotracers, its utility continues to grow, empowering healthcare experts to delve deeper into disease mechanisms, treatment responses, and personalized medical approaches. This increased array of applications not only elevates patient care standards, but also increases the demand for PET imaging systems, thus significantly contributing to the widespread adoption and continuous growth of the global positron emission tomography market. In addition, the device's maximized sensitivity can be used to reduce the dosage and offer faster diagnosis, which will expand the application of PET scans across the healthcare domain.
Establishment of Research Facilities
The establishment of new research facilities is a key driving factor for the global positron emission tomography market. These centers act as innovation hubs, nurturing the advancement of cutting-edge PET imaging technologies, radiotracers, and methods. They facilitate joint research endeavors, support the exploration of various medical applications, and help improve PET's effectiveness in diagnosing and tracking different conditions. These initiatives not only draw investments and collaborations, but also expedite the development of PET technology, amplifying its influence on healthcare. This process stimulates market expansion and guarantees ongoing progress in diagnostic capabilities.
For example, the establishment of The Australian National Total Body PET Facility occurred on December 12th, 2023. Marking Australia's inaugural total body PET scanner available for unrestricted research use, this facility is poised to propel progress in cancer research, neurological disorders, cardiovascular disease studies, and pharmaceutical development. Its implementation aims to minimize scanning durations and radiation exposure, thereby revolutionizing patient care standards.
Government Initiatives
Governments around the globe are proactively implementing strategies to drive the advancement of the global positron emission tomography market. These strategies involve financing research, promoting technological progress, and improving the availability of PET technology. By supporting R&D, governments encourage the evolution of PET imaging, nurturing the development of advanced imaging systems and innovative radiotracers. Moreover, initiatives to improve reimbursement policies and healthcare infrastructure play a major role in driving the adoption of PET scan. These extensive government initiatives aim to strengthen the PET market, fostering its expansion and reinforcing its essential role in contemporary diagnostic medicine.
For instance, in November 2023, as a part of the Chief Minister's Comprehensive Health Insurance Scheme, Coimbatore Medical College Hospital (CMCH) received a boost with the commissioning of a PET CT (Positron emission tomography and computed tomography) scan machine worth INR 12 crore. At the CMCH, the procedure, which would have cost INR 20,000 in private hospitals, would only cost INR 6,500 to INR 11,000, with the Chief Minister's insurance plan covering the cost.
Increasing Use of PET Scan in Oncology
The use of PET in oncology is significantly driving the global market. PET imaging's accuracy in identifying and tracking cancerous developments supports early detection, precise staging, and evaluation of treatment response. Its capacity to offer comprehensive metabolic insights into tumors aids oncologists in making informed decisions. As PET technology advances persistently and new radiotracers emerge, its role in oncology is also growing. This progression not only enhances patient results, but also substantially bolsters the global adoption and growth of PET technology.
For instance, Meilleur Technologies, Inc. unveiled a research collaboration pact with the Young Blood Institute (YBI) on exploring the application of Meilleur's [F-18]NAV-4694, an investigative imaging agent, in positron emission tomography examinations. This device is designed to evaluate the presence of amyloid plaque within the brain. Amyloid plaques signify a prominent feature across various neurodegenerative conditions, notably Alzheimer's disease.
Advanced Software Solutions in Positron Emission Tomography
The increasing demand for PET software solutions is acting as a driving force behind the expansion of the global positron emission tomography market. With healthcare institutions progressively depending on PET imaging for precise disease diagnosis and monitoring treatments, there's a growing requirement for advanced software that improves image processing, analysis, and interpretation. Advanced PET software enhances workflow efficiency, facilitates precise data analysis, and improves the integration of PET scans with other imaging methods. This increased demand not only enhances the effectiveness of PET technology, but also contributes to market growth by meeting the changing demands of healthcare practitioners to deliver enhanced patient care.
For example, in May 2023, Precision DL (GE HealthCare), an AI-driven image processing software, received 510(k) clearance from the Food and Drug Administration (FDA). This software is anticipated to deliver notable enhancements in contrast-to-noise ratio (CNR), precision in quantifying features, and the ability to diagnose small lesions in PET scans.
Future Market Scenario (2024-2031F)
The future of the global positron emission tomography market exhibits remarkable promise, poised for substantial expansion. Various factors are contributing to this positive projection. Advancements in PET technology, encompassing enhanced imaging resolution, faster scan speeds, and the creation of novel radiotracers are expanding PET scan applications with increased accuracy. Furthermore, the surge in chronic diseases worldwide, alongside a growing elderly population, is increasing the demand for precise diagnostic tools like PET scans. Additionally, PET's diversified usage spanning beyond oncology into segments like neurology, cardiology, and psychiatric disorders solidifies its significance in healthcare diagnostics. Collaborative endeavors between public and private sectors, reinforced by supportive government measures and improved reimbursement policies, foster market growth. Besides this, ongoing research and technological advancements are expected to position the global positron emission tomography market for notable progress and evolution in the coming years.
Key Players Landscape and Outlook
Key global positron emission tomography market players are establishing strategic alliances. These partnerships among leading firms seek to combine resources, knowledge, and technologies, aiming to propel advancements in PET imaging. These collaborations focus on stimulating innovation, creating state-of-the-art PET systems, and pioneering new radiotracers. Such affiliations enable the integration of diverse strengths, fostering research and expediting the introduction of advanced PET solutions. Ultimately, these initiatives are driving the market's progression, ensuring refined diagnostic accuracy and substantially contributing to PET technology's global growth and progression.
In September 2023, Jubilant DraxImage Inc., operating as Jubilant Radiopharma, a wholly owned subsidiary of Jubilant Pharma Limited, initiated an exclusive collaboration with Cardiac Imaging, Inc. in Oakbrook Terrace, Illinois. The partnership aims to offer healthcare facilities a daily-leased rubidium solution for conducting cardiac PET scans, thereby enhancing access to cutting-edge cardiac PET imaging for patients suspected of coronary artery disease (CAD).
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work